Evidence map›Paper›PMID 42453238›Full record

ArticleJournal of family medicine and primary care2026

Comparison of characteristics of drug-resistant

Xiao Fu, Tongxin Li, Tao Shi, Guobin Deng, Chuanyu Liao, Xiaoping Nie, Song Yang, Bohao Jiang, Lijun Yang, Ling Jiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of family medicine and primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiao FuDepartment of Medical Laboratory, Chongqing Public Health Medical Center (Affiliated Public Health Hospital of Chongqing Medical University), No. 109, Baoyu Road, Shapingba District, Chongqing 400036, China.
Tongxin LiDepartment of Medical Laboratory, Chongqing Public Health Medical Center (Affiliated Public Health Hospital of Chongqing Medical University), No. 109, Baoyu Road, Shapingba District, Chongqing 400036, China.
Tao ShiDepartment of Orthopedics, Shenzhen Qianhai Taikang Hospital, Nanshan District, Shenzhen, Guangdong Province, China.
Guobin DengMedical Insurance Department, Chongqing Public Health Medical Center (Affiliated Public Health Hospital of Chongqing Medical University), No. 109, Baoyu Road, Shapingba District, Chongqing 400036, China.
Chuanyu LiaoDepartment of Medical Laboratory, Chongqing Public Health Medical Center (Affiliated Public Health Hospital of Chongqing Medical University), No. 109, Baoyu Road, Shapingba District, Chongqing 400036, China.
Xiaoping NieDepartment of Medical Laboratory, Chongqing Public Health Medical Center (Affiliated Public Health Hospital of Chongqing Medical University), No. 109, Baoyu Road, Shapingba District, Chongqing 400036, China.
Song YangComprehensive Internal Medicine Department, Chongqing Public Health Medical Center (Affiliated Public Health Hospital of Chongqing Medical University), No. 109, Baoyu Road, Shapingba District, Chongqing 400036, China.
Bohao JiangDepartment of Urology, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Lijun YangGeneral Surgery, Chongqing Public Health Medical Center (Affiliated Public Health Hospital of Chongqing Medical University), No. 109, Baoyu Road, Shapingba District, Chongqing 400036, China.
Ling JiangThe Third Department of Tuberculosis, Chongqing Public Health Medical Center (Affiliated Public Health Hospital of Chongqing Medical University), No. 109, Baoyu Road, Shapingba District, Chongqing 400036, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Objective: This study aimed to compare the characteristics of DR-MTB from patients with PTB between primary treatment (PT) and retreatment (RT). Materials and Methods: Patients with DR-PTB, including primary treatment (DR-PTB-PT) and retreatment (DR-PTB-RT), were retrospectively studied from January 2020 to December 2023. Demographic data were collected. All the isolates were cultured using Roche culture method, drug susceptibility test (DST) using the proportion method, and detect the gene mutation using the real-time fluorescent polymerase chain reaction melting curve analysis method (MCA). Results: There were 123 patients with DR-PTB-PT and 133 patients with DR-PTB-RT included in this study. There were no significant differences on mean age, gender, living regions, and residence between two groups. There was a significant difference on phenotypic ( Conclusion: The codons of RpoB529-533, KatG315, Emb306, and GyrA88-94 were main gene mutation sites in the DR-PTB-PT and DR-PTB-RT in the local southwest regions of China. The poly-DR and comorbidity were the risk factors of DR-PTB-RT.

Indexed as

Drug resistancemycobacterium tuberculosisprimary treatmentpulmonaryreoccurrence

Identifiers

PMID42453238
PMCPMC13367656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.